Bayer Schering/Sonus’ Tocosol Paclitaxel Fails Phase III Pivotal Breast Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Tocosol paclitaxel Phase III trial fails to meet primary endpoint on noninferiority compared to Taxol control arm; trials discontinued, agreement with Bayer Schering could end, Sonus announces.
You may also be interested in...
Stock Watch: Lilly’s Emgality Trod A Well-Beaten Path To Clinical Failure
The outcome of any clinical study is uncertain but the choice of active comparator and sometimes even the placebo arm can magnify unpredictability. Emgality’s recent head-to-head failure in migraine is just the latest in a long list of casualties.
Sonus, OncoGenex Merge Into Specialty Oncology Company
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.
Sonus, OncoGenex Merge Into Specialty Oncology Company
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.